Preoperative ctDNA Detects Occult Nodal Metastasis and Predicts Recurrence in Early-Stage Esophageal Squamous Cell Carcinoma
Posted inGeneral Surgery news Oncology Pathology & Lab Medicine

Preoperative ctDNA Detects Occult Nodal Metastasis and Predicts Recurrence in Early-Stage Esophageal Squamous Cell Carcinoma

A multi-center study demonstrates that preoperative ctDNA detection significantly outperforms traditional clinical criteria in predicting nodal upstaging and survival outcomes for patients with clinical stage I/II ESCC, potentially redefining neoadjuvant treatment strategies.
Beyond Concentration: The MUCQ Score Redefines Chronic Bronchitis Identification
Posted innews Pathology & Lab Medicine Respiratory

Beyond Concentration: The MUCQ Score Redefines Chronic Bronchitis Identification

Researchers introduce the Mucin Quantitative Score (MUCQ), a novel metric combining mucin concentration and composition. Validated in the SPIROMICS cohort, MUCQ outperforms traditional total mucin measurements in identifying chronic bronchitis, offering a more precise tool for diagnosing and tracking muco-obstructive lung diseases.
Postoperative Lymph ctDNA Outperforms Plasma in Predicting Early Recurrence of HPV-Independent Head and Neck Cancer
Posted innews Oncology Otorhinolaryngology Pathology & Lab Medicine

Postoperative Lymph ctDNA Outperforms Plasma in Predicting Early Recurrence of HPV-Independent Head and Neck Cancer

Research identifies postoperative lymphatic exudate as a superior source of ctDNA for detecting molecular residual disease in HPV-independent head and neck cancer. This proximal liquid biopsy significantly outperforms plasma in predicting locoregional recurrence and may refine adjuvant treatment decisions for intermediate-risk patients.
Precision Post-CDK4/6i Management: Molecular Stratification Redefines Second-Line Therapy in HR+ Advanced Breast Cancer
Posted innews Oncology Pathology & Lab Medicine

Precision Post-CDK4/6i Management: Molecular Stratification Redefines Second-Line Therapy in HR+ Advanced Breast Cancer

This systematic review and network meta-analysis of 20 randomized trials demonstrate that molecular profiling for ESR1 and PI3K-AKT-PTEN alterations is essential for optimizing endocrine-based strategies after CDK4/6 inhibitor progression, identifying superior combination regimens for specific genomic subgroups.
Predicting Alzheimer’s Progression: The Power of Tau-Clinical Mismatch in Identifying Copathology and Resilience
Posted inNeurology news Pathology & Lab Medicine

Predicting Alzheimer’s Progression: The Power of Tau-Clinical Mismatch in Identifying Copathology and Resilience

This study demonstrates that the mismatch between tau burden and clinical symptoms identifies individuals with non-AD copathology or cognitive resilience. These findings offer a precision medicine framework for predicting disease trajectories and monitoring responses to emerging anti-amyloid therapies.
Early‑Onset Colorectal Cancer: Parsing an Epidemiologic Artifact from True Molecular Signals — Toward a Clinically Actionable Molecular Taxonomy
Posted inGastroenterology news Oncology Pathology & Lab Medicine

Early‑Onset Colorectal Cancer: Parsing an Epidemiologic Artifact from True Molecular Signals — Toward a Clinically Actionable Molecular Taxonomy

Integrated analysis shows a 2013 NEN classification change inflated EOCRC counts in the youngest adults, while independent molecular studies reveal distinct hypermutated and non‑hypermutated EOCRC subtypes with higher MSI/TMB and pathway-specific differences across populations. Implications for diagnosis, surveillance, and precision therapy are discussed.
Common, Rare and Somatic Genetic Drivers Together Double 5‑Year Atrial Fibrillation Risk: Toward an Integrated Genomic Model (IGM‑AF)
Posted inCardiology news Pathology & Lab Medicine

Common, Rare and Somatic Genetic Drivers Together Double 5‑Year Atrial Fibrillation Risk: Toward an Integrated Genomic Model (IGM‑AF)

A UK Biobank whole‑genome study finds polygenic, rare monogenic, and somatic (CHIP) variants each independently associate with incident atrial fibrillation (AF); combined genomic profiling plus clinical risk (CHARGE‑AF) improves discrimination (C=0.80) and reclassification.
Preoperative Clues That Predict Who Will Receive Adjuvant Therapy After Surgery for Oral Cavity Cancer
Posted innews Oncology Otorhinolaryngology Pathology & Lab Medicine

Preoperative Clues That Predict Who Will Receive Adjuvant Therapy After Surgery for Oral Cavity Cancer

In a multicenter cohort of 3,980 oral cavity squamous cell carcinoma patients, preoperative clinical and tumor features—including age, comorbidity, tumor subsite, size, clinical stage, and biopsy grade—predicted receipt and intensity of adjuvant therapy, with a predictive model AUC of 0.84.
ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: DYNAMIC-III Validates Prognosis but Questions Intensification
Posted inGastroenterology news Oncology Pathology & Lab Medicine

ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: DYNAMIC-III Validates Prognosis but Questions Intensification

The randomized phase 2/3 DYNAMIC-III trial shows that postoperative circulating tumor DNA (ctDNA) strongly stratifies recurrence risk in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations with outcomes close to standard care; escalation for ctDNA-positive disease did not improve recurrence-free survival.
ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: Prognostic Validation but No Benefit from Chemotherapy Intensification — Key Findings from the DYNAMIC-III Randomized Phase 2/3 Trial
Posted innews Oncology Pathology & Lab Medicine

ctDNA-Guided Adjuvant Therapy in Stage III Colon Cancer: Prognostic Validation but No Benefit from Chemotherapy Intensification — Key Findings from the DYNAMIC-III Randomized Phase 2/3 Trial

The DYNAMIC-III trial validates circulating tumor DNA (ctDNA) as a strong prognostic marker in stage III colon cancer. ctDNA-guided de-escalation reduced oxaliplatin exposure and hospitalizations with near-standard outcomes, but escalation for ctDNA-positive patients failed to improve recurrence-free survival.